Qilian International Holding Group Limited (BGM) - Total Liabilities

Latest as of September 2025: $41.68 Million USD

Based on the latest financial reports, Qilian International Holding Group Limited (BGM) has total liabilities worth $41.68 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Qilian International Holding Group Limit's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Qilian International Holding Group Limited - Total Liabilities Trend (2017–2025)

This chart illustrates how Qilian International Holding Group Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Qilian International Holding Group Limit.

Qilian International Holding Group Limited Competitors by Total Liabilities

The table below lists competitors of Qilian International Holding Group Limited ranked by their total liabilities.

Company Country Total Liabilities
RiTdisplay Corp
TW:8104
Taiwan NT$5.23 Billion
Serrano 61 Desarrollo SOCIMI SA
MC:YSRR
Spain €36.97 Million
Chung Fu Tex-International Corp
TW:1435
Taiwan NT$185.59 Million
Immobile
WAR:GKI
Poland zł834.88 Million
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
Taiwan NT$1.01 Billion
Catur Sentosa Adiprana Tbk
JK:CSAP
Indonesia Rp8.56 Trillion
Tsang Yow Industrial Co Ltd
TW:1568
Taiwan NT$353.63 Million
Nasmedia Co. Ltd
KQ:089600
Korea ₩185.10 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Qilian International Holding Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Qilian International Holding Group Limit net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.24 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qilian International Holding Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qilian International Holding Group Limited (2017–2025)

The table below shows the annual total liabilities of Qilian International Holding Group Limited from 2017 to 2025.

Year Total Liabilities Change
2025-09-30 $41.68 Million +367.73%
2024-09-30 $8.91 Million +29.01%
2023-09-30 $6.91 Million -27.78%
2022-09-30 $9.56 Million -48.82%
2021-09-30 $18.68 Million -3.20%
2020-09-30 $19.30 Million +52.82%
2019-09-30 $12.63 Million -19.13%
2018-09-30 $15.62 Million -20.82%
2017-09-30 $19.73 Million --

About Qilian International Holding Group Limited

NASDAQ:BGM USA Drug Manufacturers - Specialty & Generic
Market Cap
$98.58 Million
Market Cap Rank
#19335 Global
#4435 in USA
Share Price
$0.26
Change (1 day)
+0.43%
52-Week Range
$0.25 - $11.75
All Time High
$58.32
About

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufactu… Read more